Global Vaccines: A Shot Of Growth For GSK And Pfizer?
Recent M&A activity in the vaccine industry has narrowed the pool of players. For companies that remain, the opportunity to reshape their positions in the global market comes with an even greater responsibility to contribute meaningfully to continued advances in global public health.
You may also be interested in...
Although cancer grabs the spotlight for harnessing the immune system against tumors, other therapeutic areas and modalities are being developed in the shadows. Genocea Biosciences thinks it has a surefire way to identify novel antigens for T-cell vaccines. It hopes to shake up large infectious disease markets, and more.
The technology could speed the development of prophylactic and therapeutic conjugated vaccines against difficult-to-treat bacterial infections, and the two companies are planning an innovative collaboration that will see GlycoVaxyn retain its autonomy and agility.
Novartis is overhauling its pharma business by exchanging selected assets with GlaxoSmithKline and divesting its animal health business to Eli Lilly. Worth more than $25 billion, the complex corporate deal will boost the Swiss group’s oncology unit and create a consumer health joint venture, while divesting its vaccine unit to GSK.